Pfizer (PFE) stock price, revenue, and financials

Pfizer market cap is $208.3 b, and annual revenue was $51.75 b in FY 2019

$208.3 B

PFE Mkt cap, 22-May-2020

$12 B

Pfizer Revenue Q1, 2020
Pfizer Gross profit (Q1, 2020)9.7 B
Pfizer Gross profit margin (Q1, 2020), %80.2%
Pfizer Net income (Q1, 2020)3.4 B
Pfizer EBIT (Q1, 2020)3.4 B
Pfizer Cash, 29-Mar-20202.2 B
Pfizer EV258.4 B

Pfizer Revenue

Pfizer revenue was $51.75 b in FY, 2019

Embed Graph

Pfizer Revenue Breakdown

Embed Graph

Pfizer revenue breakdown by business segment: 40.2% from Essential Health and 59.8% from Innovative Health

Pfizer revenue breakdown by geographic segment: 49.5% from United States, 16.2% from Developed Europe, 12.6% from Developed Rest of World and 21.7% from Emerging Markets

Pfizer Income Statement

Annual

USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

48.9b52.8b52.5b53.6b51.8b

Revenue growth, %

(2%)8%(1%)

Cost of goods sold

9.6b12.3b11.2b11.2b10.2b

Gross profit

39.2b40.5b41.3b42.4b41.5b

Gross profit Margin, %

80%77%79%79%80%

Sales and marketing expense

14.8b14.8b14.8b

R&D expense

7.7b7.9b7.7b8.0b8.7b

General and administrative expense

14.5b14.4b

Operating expense total

22.5b22.7b22.4b22.5b23.0b

Depreciation and amortization

3.7b4.1b4.8b

EBIT

7.0b7.2b21.4b

EBIT margin, %

14%14%41%

Pre tax profit

9.0b8.4b12.3b11.9b17.7b

Income tax expense

2.0b1.1b(9.0b)706.0m1.4b

Net Income

7.0b7.2b21.3b11.2b16.3b

Pfizer Balance Sheet

Annual

USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

3.6b2.6b1.3b1.1b1.3b

Accounts Receivable

8.0b8.7b

Prepaid Expenses

2.5b2.6b

Inventories

7.5b6.8b7.6b7.5b8.3b

Current Assets

43.8b38.9b41.1b49.9b32.8b

PP&E

13.8b13.3b13.9b13.4b14.0b

Goodwill

48.2b54.4b56.0b53.4b58.7b

Total Assets

167.4b171.6b171.8b159.0b167.5b

Accounts Payable

3.6b4.5b4.7b4.7b4.2b

Dividends Payable

1.9b1.9b2.0b2.0b2.1b

Short-term debt

10.2b10.7b10.0b13.6b17.7b

Current Liabilities

29.4b31.1b30.4b31.9b37.3b

Long-term debt

28.7b31.4b33.5b32.9b36.0b

Total Debt

38.9b42.1b43.5b32.9b53.6b

Total Liabilities

102.4b111.8b100.1b95.7b104.0b

Common Stock

459.0m461.0m464.0m467.0m468.0m

Preferred Stock

26.0m24.0m21.0m19.0m17.0m

Additional Paid-in Capital

81.0b82.7b84.3b86.3b87.4b

Retained Earnings

72.0b71.8b85.3b89.6b97.7b

Total Equity

65.0b59.8b71.7b63.8b63.4b

Debt to Equity Ratio

0.6 x0.7 x0.6 x0.5 x

Debt to Assets Ratio

0.2 x0.2 x0.3 x0.2 x

Financial Leverage

2.6 x2.9 x2.4 x2.5 x2.6 x

Quarterly

USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Cash

2.6b3.4b2.1b4.1b2.6b2.8b2.3b2.7b3.6b1.9b1.8b2.8b2.2b

Accounts Receivable

9.6b9.8b9.4b9.9b

Prepaid Expenses

2.6b2.5b3.0b

Inventories

7.6b7.6b7.5b7.4b7.6b7.9b8.1b8.1b8.2b8.0b8.2b8.2b8.4b

Current Assets

41.3b43.8b38.5b35.9b36.4b40.3b34.8b37.3b41.6b45.3b47.1b33.5b34.7b

PP&E

13.6b13.6b13.3b13.2b13.4b13.5b14.0b13.9b14.0b13.5b13.5b13.7b14.0b

Goodwill

48.6b50.6b56.3b54.7b55.0b56.1b56.4b55.8b55.6b53.5b53.4b58.7b58.5b

Total Assets

162.9b170.7b178.4b168.8b168.6b172.2b164.6b165.0b167.8b155.0b156.2b170.0b166.3b

Accounts Payable

3.1b3.3b3.5b3.4b3.4b3.5b3.9b4.2b4.3b4.2b4.0b3.9b4.0b

Dividends Payable

1.8b1.8b1.9b1.9b2.0b2.0b2.0b2.0b

Short-term debt

11.5b13.7b13.6b768.0m9.5b9.4b9.0b11.6b7.4b9.4b10.5b16.6b16.0b

Current Liabilities

28.7b32.1b34.8b24.9b27.2b28.2b27.4b32.2b29.0b29.4b32.0b37.0b33.9b

Long-term debt

27.8b30.5b30.4b36.3b34.2b34.5b31.8b28.9b33.7b35.7b36.2b36.0b36.3b

Total Debt

39.4b44.2b44.1b37.1b43.7b44.0b40.8b40.5b41.0b35.7b46.7b52.7b52.3b

Total Liabilities

99.6b107.6b114.8b110.0b109.9b111.0b94.1b94.9b96.2b96.3b96.3b105.1b101.0b

Common Stock

460.0m461.0m461.0m463.0m463.0m463.0m465.0m465.0m466.0m468.0m468.0m468.0m470.0m

Preferred Stock

26.0m25.0m25.0m23.0m23.0m22.0m21.0m20.0m20.0m19.0m18.0m18.0m17.0m

Additional Paid-in Capital

81.4b82.1b82.5b83.1b83.4b83.8b84.6b84.9b85.8b86.6b87.0b87.1b87.7b

Retained Earnings

75.0b73.4b72.8b74.8b74.1b75.0b90.0b89.9b92.0b93.4b94.4b100.1b101.0b

Total Equity

63.3b63.1b63.6b58.7b58.7b61.1b70.5b70.1b71.7b59.2b59.9b65.4b65.3b

Debt to Equity Ratio

0.6 x0.7 x0.7 x0.6 x0.7 x0.7 x0.6 x0.6 x0.6 x0.6 x

Debt to Assets Ratio

0.2 x0.3 x0.2 x0.2 x0.3 x0.3 x0.2 x0.2 x0.2 x0.2 x

Financial Leverage

2.6 x2.7 x2.8 x2.9 x2.9 x2.8 x2.3 x2.4 x2.3 x2.6 x2.6 x2.6 x2.5 x

Pfizer Cash Flow

Annual

USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

7.0b7.2b21.4b11.2b16.3b

Depreciation and Amortization

5.2b5.8b6.3b6.4b6.0b

Accounts Receivable

21.0m(134.0m)259.0m(644.0m)(742.0m)

Inventories

(199.0m)365.0m(357.0m)(717.0m)(1.0b)

Accounts Payable

254.0m871.0m46.0m431.0m(564.0m)

Cash From Operating Activities

14.7b15.9b16.5b15.8b12.6b

Purchases of PP&E

(1.4b)(1.8b)(2.0b)(2.0b)(2.2b)

Cash From Investing Activities

(3.0b)(7.8b)(4.7b)4.5b(3.9b)

Short-term Borrowings

(4.0b)(5.1b)(10.0b)(4.4b)(8.4b)

Long-term Borrowings

(3.0b)(7.7b)(6.2b)(3.6b)(6.8b)

Dividends Paid

(6.9b)(7.3b)(7.7b)(8.1b)(8.2b)

Cash From Financing Activities

(10.4b)(8.9b)(13.0b)(20.4b)(8.5b)

Net Change in Cash

298.0m(1.0b)(1.3b)(205.0m)125.0m

Interest Paid

1.3b1.5b1.5b1.3b1.6b

Income Taxes Paid

2.4b2.5b2.5b3.7b3.7b

Quarterly

USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Net Income

3.0b5.1b6.5b3.1b6.2b9.1b3.6b7.4b11.6b3.9b8.9b16.6b3.4b

Depreciation and Amortization

1.4b2.8b4.2b1.6b3.1b4.7b1.6b3.1b4.7b

Cash From Operating Activities

1.8b5.4b1.0b1.6b4.8b9.7b2.0b5.8b11.1b1.7b4.3b8.8b3.1b

Purchases of PP&E

(301.0m)(702.0m)(1.1b)(358.0m)(806.0m)(1.3b)(386.0m)(810.0m)(1.4b)(460.0m)(939.0m)(1.5b)(463.0m)

Cash From Investing Activities

4.4b(323.0m)(4.7b)4.8b3.0b19.0m9.7b8.2b5.3b7.6b5.6b(1.1b)(71.0m)

Short-term Borrowings

(1.3b)(2.3b)(3.3b)(2.5b)(5.1b)(7.7b)(83.0m)(2.9b)(4.2b)(3.8b)(2.4b)(4.1b)(7.6b)

Long-term Borrowings

(1.5b)(4.3b)(4.3b)(1.3b)(4.5b)(4.5b)(355.0m)(3.1b)(3.1b)(3.0b)(5.4b)(5.8b)(2.2b)

Dividends Paid

(1.9b)(3.7b)(5.5b)(1.9b)(3.9b)(5.7b)(2.0b)(4.0b)(6.0b)(68.0m)(4.1b)(6.1b)(71.0m)

Cash From Financing Activities

(7.1b)(5.3b)(6.9b)(4.9b)(7.9b)(9.6b)(10.7b)(12.6b)(14.0b)(8.5b)(9.3b)(6.0b)(2.2b)

Net Change in Cash

(1.1b)(230.0m)(1.5b)1.5b(5.0m)193.0m985.0m1.4b2.2b792.0m612.0m1.6b846.0m

Interest Paid

409.0m903.0m1.2b216.0m881.0m1.1b259.0m724.0m968.0m385.0m809.0m1.2b472.0m

Income Taxes Paid

518.0m1.1b1.4b195.0m1.1b1.4b257.0m1.2b1.7b235.0m2.1b2.6b239.0m

Pfizer Ratios

USDY, 2020

EV/EBIT

76 x

EV/CFO

82.5 x

Financial Leverage

2.5 x

Pfizer Operating Metrics

Pfizer's Properties was reported to be 501 in FY, 2017.
FY, 2014FY, 2015FY, 2016FY, 2017

Active Clinical Studies

448 338

Phase III Trials Products

22 30 34 29

Discovery Projects

91 90 96 87

Countries

125 125

Manufacturing Sites

55 64 63 58

Properties

513 595 567 501

Total Units Delivered

74 b

Vaccines Delivered

135 m

Pfizer Sustainability Metrics

 FY, 2018

Water Withdrawn

16.30 m cubic meters

Nonhazardous Waste (Recycled)

23 k metric tons

Nonhazardous Waste (Disposed)

26.70 k metric tons

Hazardous Waste (Recycled)

17.60 k metric tons

Hazardous Waste (Disposed)

70.10 k metric tons

Greenhouse Gas Emissions (Scope 2)

920 k metric tons of carbon dioxide equivalent

Greenhouse Gas Emissions (Scope 1)

760 k metric tons of carbon dioxide equivalent

Energy Used

20.30 k TJ

Pfizer Employee Rating

4.04087 votes
Culture & Values
4.0
Work/Life Balance
3.9
Senior Management
3.6
Salary & Benefits
4.0
Career Opportunities
3.6
Source